Immunogenicity of intrathecal plasmid gene delivery: cytokine release and effects on transgene expression

Background One method for the delivery of therapeutic proteins to the spinal cord is to inject nonviral gene vectors including plasmid DNA into the cerebrospinal fluid (CSF) that surrounds the spinal cord (intrathecal space). This approach has produced therapeutic benefits in animal models of diseas...

Full description

Saved in:
Bibliographic Details
Published inThe journal of gene medicine Vol. 11; no. 9; pp. 782 - 790
Main Authors Hughes, Travis S., Langer, Stephen J., Virtanen, Salla I., Chavez, Raymond A., Watkins, Linda R., Milligan, Erin D., Leinwand, Leslie A.
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.09.2009
Wiley Periodicals Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background One method for the delivery of therapeutic proteins to the spinal cord is to inject nonviral gene vectors including plasmid DNA into the cerebrospinal fluid (CSF) that surrounds the spinal cord (intrathecal space). This approach has produced therapeutic benefits in animal models of disease and several months of protein expression; however, there is little information available on the immune response to these treatments in the intrathecal space, the relevance of plasmid CpG sequences to any plasmid‐induced immune response, or the effect of this immune response on transgene expression. Methods In the present study, coding or noncoding plasmids were delivered to the intrathecal space of the lumbar spinal region in rats. Lumbosacral CSF was then collected at various time points afterwards for monitoring of cytokines and transgene expression. Results This work demonstrates, for the first time, increased tumor necrosis factor‐α and interleukin‐1 in response to intrathecal plasmid vector injection and provides evidence indicating that this response is largely absent in a CpG‐depleted vector. Transgene expression in the CSF is not significantly affected by this immune response. Expression after intrathecal plasmid injection is variable across rats but correlates with the amount of tissue associated plasmid and is increased by disrupting normal CSF flow. Conclusions The data obtained in the present study indicate that plasmid immunogenicity may affect intrathecal plasmid gene therapy safety but not transgene expression in the CSF. Furthermore, the development of methods to prevent loss of plasmid via CSF flow out of the central nervous system through the injection hole and/or natural outflow routes may increase intrathecal plasmid gene delivery efficacy. Copyright © 2009 John Wiley & Sons, Ltd.
Bibliography:ark:/67375/WNG-FQFKV712-F
ArticleID:JGM1364
NIH - No. GM29090; No. DA024044; No. DA015642; No. NIDA 018156
Supporting Information
istex:2A0285B9C0690963497F6FF4B12AC8AEBD26A508
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:1099-498X
1521-2254
1521-2254
DOI:10.1002/jgm.1364